Actinium Pharmaceuticals' (ATNM) "Buy" Rating Reaffirmed at

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a report issued on Monday, Benzinga reports. They currently have a $50.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q2 2024 earnings at ($0.38) EPS, Q3 2024 earnings at ($0.45) EPS, […]

Related Keywords

, Creative Financial Designs Inc , Analyst Recommendations For Actinium Pharmaceuticals , News Ratings For Actinium Pharmaceuticals Daily , Actinium Pharmaceuticals Inc , Actinium Pharmaceuticals , Maxim Group , Cantor Fitzgerald , Sanders Morris Harris , Brandywine Global Investment Management , Actinium Pharmaceuticals Stock , Free Report , Moderate Buy , Get Free Report , Global Investment Management , Financial Designs , Actinium Pharmaceuticals Daily , Nyseamerican Atnm , Atnm , Medical , Reiterated Rating , Hc Wainwright ,